These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 34116355)

  • 41. Steatohepatitic Variant of Hepatocellular Carcinoma Is Associated With Both Alcoholic Steatohepatitis and Nonalcoholic Steatohepatitis: A Study of 2 Cohorts With Molecular Insights.
    Qin J; Higashi T; Nakagawa S; Fujiwara N; Yamashita YI; Beppu T; Baba H; Kobayashi M; Kumada H; Gunasekaran G; Schiano TD; Thung SN; Fiel MI; Hoshida Y; Ward SC
    Am J Surg Pathol; 2020 Oct; 44(10):1406-1412. PubMed ID: 32618599
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
    Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
    J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Blocking sphingosine 1-phosphate receptor 2 accelerates hepatocellular carcinoma progression in a mouse model of NASH.
    Yoshida T; Tsuchiya A; Kumagai M; Takeuchi S; Nojiri S; Watanabe T; Ogawa M; Itoh M; Takamura M; Suganami T; Ogawa Y; Terai S
    Biochem Biophys Res Commun; 2020 Oct; 530(4):665-672. PubMed ID: 32768187
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Gut insulin action protects from hepatocarcinogenesis in diabetic mice comorbid with nonalcoholic steatohepatitis.
    Soeda K; Sasako T; Enooku K; Kubota N; Kobayashi N; Ikushima YM; Awazawa M; Bouchi R; Toda G; Yamada T; Nakatsuka T; Tateishi R; Kakiuchi M; Yamamoto S; Tatsuno K; Atarashi K; Suda W; Honda K; Aburatani H; Yamauchi T; Fujishiro M; Noda T; Koike K; Kadowaki T; Ueki K
    Nat Commun; 2023 Oct; 14(1):6584. PubMed ID: 37852976
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of murine steatohepatitis models identifies a dietary intervention with robust fibrosis, ductular reaction, and rapid progression to cirrhosis and cancer.
    Wei G; An P; Vaid KA; Nasser I; Huang P; Tan L; Zhao S; Schuppan D; Popov YV
    Am J Physiol Gastrointest Liver Physiol; 2020 Jan; 318(1):G174-G188. PubMed ID: 31630534
    [TBL] [Abstract][Full Text] [Related]  

  • 46. High-fat diet combined with dextran sulfate sodium failed to induce a more serious NASH phenotype than high-fat diet alone.
    Zhou Y; Feng Y; Yang L; Zheng P; Hang L; Jiang F; Yuan J; Zhu L
    Front Pharmacol; 2022; 13():1022172. PubMed ID: 36238563
    [No Abstract]   [Full Text] [Related]  

  • 47. RNA helicase DEAD-box protein 5 alleviates nonalcoholic steatohepatitis progression via tethering TSC complex and suppressing mTORC1 signaling.
    Zhang Y; Ye S; Lu W; Zhong J; Leng Y; Yang T; Luo J; Xu W; Zhang H; Kong L
    Hepatology; 2023 May; 77(5):1670-1687. PubMed ID: 35796622
    [TBL] [Abstract][Full Text] [Related]  

  • 48. High fat diet exacerbates dextran sulfate sodium induced colitis through disturbing mucosal dendritic cell homeostasis.
    Cheng L; Jin H; Qiang Y; Wu S; Yan C; Han M; Xiao T; Yan N; An H; Zhou X; Shao Q; Xia S
    Int Immunopharmacol; 2016 Nov; 40():1-10. PubMed ID: 27567245
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Different roles of FAT10, FOXO1, and ADRA2A in hepatocellular carcinoma tumorigenesis in patients with alcoholic steatohepatitis (ASH) vs non-alcoholic steatohepatitis (NASH).
    Jia Y; French B; Tillman B; French S
    Exp Mol Pathol; 2018 Aug; 105(1):144-149. PubMed ID: 30009772
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Retinoid acid induced 16 deficiency aggravates colitis and colitis-associated tumorigenesis in mice.
    Xu YL; Ding CL; Qian CL; Qi ZT; Wang W
    Cell Death Dis; 2019 Dec; 10(12):958. PubMed ID: 31862898
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The SGLT2 Inhibitor Canagliflozin Prevents Carcinogenesis in a Mouse Model of Diabetes and Non-Alcoholic Steatohepatitis-Related Hepatocarcinogenesis: Association with SGLT2 Expression in Hepatocellular Carcinoma.
    Jojima T; Wakamatsu S; Kase M; Iijima T; Maejima Y; Shimomura K; Kogai T; Tomaru T; Usui I; Aso Y
    Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31652578
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Supervised learning reveals circulating biomarker levels diagnostic of hepatocellular carcinoma in a clinically relevant model of non-alcoholic steatohepatitis; An OAD to NASH.
    Hwang A; Shi C; Zhu E; Naaz F; Zhou P; Rasheed Z; Liu M; Jung LS; Duan B; Li J; Jiang K; Paka L; Gadhiya SV; Dana D; Ali Q; Yamin MA; Goldberg ID; Narayan P
    PLoS One; 2018; 13(6):e0198937. PubMed ID: 29944670
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Utilization of animal models to investigate nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
    Wu J
    Oncotarget; 2016 Jul; 7(27):42762-42776. PubMed ID: 27072576
    [TBL] [Abstract][Full Text] [Related]  

  • 54. An Obesogenic Dietary Mouse Model of Nonalcoholic Steatohepatitis.
    Zarrouki B; Boucher J
    Methods Mol Biol; 2020; 2164():121-127. PubMed ID: 32607889
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH.
    Shiba K; Tsuchiya K; Komiya C; Miyachi Y; Mori K; Shimazu N; Yamaguchi S; Ogasawara N; Katoh M; Itoh M; Suganami T; Ogawa Y
    Sci Rep; 2018 Feb; 8(1):2362. PubMed ID: 29402900
    [TBL] [Abstract][Full Text] [Related]  

  • 56. MUTYH is associated with hepatocarcinogenesis in a non-alcoholic steatohepatitis mouse model.
    Sakamoto H; Miyanishi K; Tanaka S; Ito R; Hamaguchi K; Sakurada A; Sato M; Kubo T; Osuga T; Murase K; Takada K; Nakabeppu Y; Kobune M; Kato J
    Sci Rep; 2021 Feb; 11(1):3599. PubMed ID: 33574380
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Semaglutide reduces tumor burden in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH-HCC with advanced fibrosis.
    Hansen HH; Pors S; Andersen MW; Vyberg M; Nøhr-Meldgaard J; Nielsen MH; Oró D; Madsen MR; Lewinska M; Møllerhøj MB; Madsen AN; Feigh M
    Sci Rep; 2023 Dec; 13(1):23056. PubMed ID: 38155202
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Key features of the environment promoting liver cancer in the absence of cirrhosis.
    Zaki MYW; Mahdi AK; Patman GL; Whitehead A; Maurício JP; McCain MV; Televantou D; Abou-Beih S; Ramon-Gil E; Watson R; Cox C; Leslie J; Wilson C; Govaere O; Lunec J; Mann DA; Nakjang S; Oakley F; Shukla R; Anstee QM; Tiniakos D; Reeves HL
    Sci Rep; 2021 Aug; 11(1):16727. PubMed ID: 34408183
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Lipid-lowering agents inhibit hepatic steatosis in a non-alcoholic steatohepatitis-derived hepatocellular carcinoma mouse model.
    Orime K; Shirakawa J; Togashi Y; Tajima K; Inoue H; Nagashima Y; Terauchi Y
    Eur J Pharmacol; 2016 Feb; 772():22-32. PubMed ID: 26724391
    [TBL] [Abstract][Full Text] [Related]  

  • 60. STARD1 promotes NASH-driven HCC by sustaining the generation of bile acids through the alternative mitochondrial pathway.
    Conde de la Rosa L; Garcia-Ruiz C; Vallejo C; Baulies A; Nuñez S; Monte MJ; Marin JJG; Baila-Rueda L; Cenarro A; Civeira F; Fuster J; Garcia-Valdecasas JC; Ferrer J; Karin M; Ribas V; Fernandez-Checa JC
    J Hepatol; 2021 Jun; 74(6):1429-1441. PubMed ID: 33515644
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.